GLP-1 medicines such as Ozempic may reduce the risk of serious bone fractures in people with type 2 diabetes, according to a large study that challenges fears the blockbuster drugs could damage bone health.
Researchers found that patients starting GLP-1 medicines had a 21% lower risk of fragility fractures over three years than comparable patients prescribed DPP-4 medicines — another class of diabetes medicines.
